Joel Isaacson & Co. LLC lowered its position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by 12.4% during the second quarter, Holdings Channel reports. The firm owned 70,660 shares of the specialty pharmaceutical company’s stock after selling 10,000 shares during the period. Joel Isaacson & Co. LLC’s holdings in AcelRx Pharmaceuticals were worth $152,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ACRX. WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares during the period. Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares during the period. ING Groep NV raised its position in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC raised its position in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the period. Institutional investors and hedge funds own 30.39% of the company’s stock.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) opened at 3.00 on Thursday. The stock’s market cap is $136.14 million. The firm has a 50 day moving average of $2.74 and a 200 day moving average of $2.77. AcelRx Pharmaceuticals, Inc. has a one year low of $1.95 and a one year high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. On average, equities research analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/acelrx-pharmaceuticals-inc-nasdaqacrx-stake-lowered-by-joel-isaacson-co-llc/1469340.html.

A number of brokerages have recently issued reports on ACRX. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Roth Capital set a $13.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $7.57.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 28.10% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Want to see what other hedge funds are holding ACRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.